Modalis Announces Completion of a Research Collaboration on Angelman Syndrome and Regaining Worldwide Rights
underway since 2020. All rights to MDL-206 will be returned to Modalis, and the Company will continue to advance the program internally. Additional research programs with Astellas will continue as currently planned. Upon the separation, Modalis regains all rights to develop gene therapies targeting Angelman Syndrome with CRISPR-GNDM® technology. This allows Modalis to fully leverage its expertise in engineering, biology, regulatory, and manufacturing of gene therapies to expand its wholly owned CRISPR-based portfolio to include Angelman Syndrome. Modalis further regains the right to partner its Angelman Syndrome programs in the future.